Guilherme Kortas

Guilherme Kortas

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2018 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
MWMaira Aguiar Werneck
Maira Aguiar Werneck
Guilherme KortasGuilherme Kortas
Guilherme Kortas
AAArthur Guerra de Andrade
Arthur Guerra de Andrade
JCJoão Mauricio Castaldelli-Maia
João Mauricio Castaldelli-Maia

14 March 2022 in Brain Sciences
Verified
Journal Article
Open access
PDF file
Luiza Larrubia Alvares FlorenceLuiza Larrubia Alvares Florence
Luiza Larrubia Alvares Florence
DLDângela Layne Silva Lassi
Dângela Layne Silva Lassi
Guilherme KortasGuilherme Kortas
Guilherme Kortas
DLDanielle R. Lima
Danielle R. Lima
CPCintia Azevedo-Marques Perico
Cintia Azevedo-Marques Perico
JCJoão Mauricio Castaldelli-Maia
João Mauricio Castaldelli-Maia
Background: Although Alcohol Use Disorder (AUD) is highly prevalent worldwide, treating this condition remains challenging. Further, potential treatments for AUD do not fully address alcohol-induced neuroadaptive changes. Understanding the effects of pharmacotherapies for AUD on the human brain may lead to tailored, more effective treatments, and improved individual clinical outcomes. Objectives: We systematically reviewed the literature for studies investigating pharmacotherapies for AUD that included neuroimaging-based treatment outcomes. We searched the PubMed, Scielo, and PsycINFO databases up to January 2021. Study eligibility criteria, participants, and interventions: Eligible studies included those investigating pharmacotherapies for AUD and employing functional magnetic resonance imaging (fMRI), positron emission tomography (PET), single-photon emission computed tomography (SPECT), and/or proton magnetic resonance spectroscopy (H-MRS). Study appraisal and synthesis methods: Two independent reviewers screened studies’ titles and abstracts for inclusion. Data extraction forms were shared among all the authors to standardize data collection. We gathered information on the following variables: sample size; mean age; sociodemographic and clinical characteristics; alcohol use status; study design and methodology; main neuroimaging findings and brain-regions of interest (i.e., brain areas activated by alcohol use and possible pharmacological interactions); and limitations of each study. Results: Out of 177 studies selected, 20 studies provided relevant data for the research topic. Findings indicate that: (1) Acamprosate and gabapentin may selectively modulate limbic regions and the anterior cingulate cortex; (2) Naltrexone and disulfiram effects may involve prefrontal, premotor, and cerebellar regions; (3) Pharmacotherapies acting on glutamate and GABA neurotransmission involve primarily areas underpinning reward and negative affective states, and; (4) Pharmacotherapies acting on opioid and dopamine systems may affect areas responsible for the cognitive and motor factors of AUD. Limitations: Most of the studies were focused on naltrexone. A small number of studies investigated the action of disulfiram and gabapentin, and no neuroimaging studies investigated topiramate. In addition, the time between medication and neuroimaging scans varied widely across studies. Conclusions: We identified key-brain regions modulated by treatments available for AUD. Some of the regions modulated by naltrexone are not specific to the brain reward system, such as the parahippocampal gyrus (temporal lobe), parietal and occipital lobes. Other treatments also modulate not specific regions of the reward system, but play a role in the addictive behaviors, including the insula and dorsolateral prefrontal cortex. The role of these brain regions in mediating the AUD pharmacotherapy response warrants investigation in future research studies.

15 August 2023 in Brain Sciences
Verified
Journal Article
Open access
PDF file
MMMatheus Cheibub David Marin
Matheus Cheibub David Marin
Maria Olivia Pozzolo PedroMaria Olivia Pozzolo Pedro
Maria Olivia Pozzolo Pedro
GPGiuliana Perrotte
Giuliana Perrotte
Anderson Sousa Martins-da-SilvaAnderson Sousa Martins-da-Silva
Anderson Sousa Martins-da-Silva
DLDângela Layne Silva Lassi
Dângela Layne Silva Lassi
JCJoão Mauricio Castaldelli-Maia
João Mauricio Castaldelli-Maia
(1) Background: The treatment of substance addiction is challenging and has persisted for decades, with only a few therapeutic options. Although there are some recommendations for specific treatments for Alcohol Use Disorder (AUD), there is no specific medication used to treat alcohol cravings, which could benefit millions of patients that are suffering from alcoholism. Cravings, or the urge to use drugs, refer to the desire to experience the effects of a previously experienced psychoactive substance. (2) Methods: We included original studies of alcohol abuse or dependence extracted from a controlled, blind, pharmacological treatment study which presented measures and outcomes related to alcohol cravings. (3) Results: Specific drugs used for the treatment of alcoholism, such as Naltrexone and Acamprosate, have had the best results in relieving craving symptoms, as well as promoting abstinence. Baclofen and anticonvulsants such as Gabapentin and Topiramate have shown good results in promoting abstinence and the cessation of cravings. (4) Conclusions: Specific drugs used for the treatment of alcoholism to obtain the best results can be considered the gold standard for promoting abstinence and relieving cravings. Anticonvulsants and Baclofen also had good results, with these medications being considered as second-line ones. Varenicline is an option for alcohol dependents who also concomitantly ingest tobacco.

19 May 2022 in International Review of Psychiatry
Verified
Journal Article
Closed access
AAAna Beatriz Balieiro Abrahão
Ana Beatriz Balieiro Abrahão
Guilherme KortasGuilherme Kortas
Guilherme Kortas
IBIsrael Kanaan Blaas
Israel Kanaan Blaas
GGGislaine Koch Gimenes
Gislaine Koch Gimenes
KLKae Leopoldo
Kae Leopoldo
JCJoão Mauricio Castaldelli-Maia
João Mauricio Castaldelli-Maia
This paper aimed to review the literature regarding the impact of discrimination on substance use disorders among Sexual Minorities (SM), with a focus on alcohol, opioids, stimulants, polydrug use, chemsex, cannabis and tobacco, as well as inequalities in the access to health care services. It is alarmingly clear that SM report higher rates of morbidity if compared to the general population. Health care delivery inequalities have also been reported in this special population. Also, the lack of data from low- and middle-income countries on substance use among SM is a major concern. Certainly, discrimination play a key-role among leading factors to substance abuse, continued use, disorders, and lower levels of preventive and treatment interventions. However, it may be difficult to estimate the impact of discrimination because of the lack of research data and different methodologies of literature studies. Moreover, SM are differently categorized and defined and evidences may be not comparable between studies. There is an urgent need of strategic guidelines and research investments aimed at prioritizing these populations disproportionately impacted by substance use. Equity-oriented policies and programs can facilitate opportunities and decrease substance use in these vulnerable subgroups, including community- and peer-led initiatives and nonjudgmental and inclusive health services.

2 January 2022 in International Review of Psychiatry
Verified
Journal Article
Closed access
Guilherme KortasGuilherme Kortas
Guilherme Kortas
AAAna Beatriz Balieiro Abrahão
Ana Beatriz Balieiro Abrahão
AMAndré Malbergier
André Malbergier
TFThiago Fidalgo
Thiago Fidalgo
HMHELENA FERREIRA MOURA
HELENA FERREIRA MOURA
JCJoão Mauricio Castaldelli-Maia
João Mauricio Castaldelli-Maia
Immigration typically occurs from low- to high-income countries and regions. Unfortunately, these wealthier areas also have higher rates of cannabis use (e.g. European Union and the US). This systematic review aimed to summarize available studies on cannabis use among immigrants, refugees, and asylum seekers. In addition, evidence on the association between immigration and cannabis use was reviewed. The rates of cannabis use were lower among immigrants than natives. The risk and protective factors to cannabis use were quite similar to those of the native populations. The population at greatest risk for cannabis use were refugees, males, singles, non-religious, those with lower educational level, living in urban areas, with friends that use cannabis and/or other drugs. Cannabis use tend to increase over generations, and acculturation seems to play a pivotal role. First generation migrants report equal or lower consumption of cannabis when compared with the majority population with a subsequent increase in following generations, with a clear association with acculturation factors. A higher cannabis use was found among migrants with lower cultural congruity as well as a higher level of culture assimilation. This use seems to be unrelated to alcohol or illicit drugs consumption, but possibly associated with tobacco smoking.

21 July 2023 in International Review of Psychiatry
Verified
Journal Article
Closed access
MPMayra Cruz Preto
Mayra Cruz Preto
Guilherme KortasGuilherme Kortas
Guilherme Kortas
IBIsrael Kanaan Blaas
Israel Kanaan Blaas
DLDangela Layne Silva Lassi
Dangela Layne Silva Lassi
MCMarcela Waisman Campos
Marcela Waisman Campos
JCJoão Mauricio Castaldelli-Maia
João Mauricio Castaldelli-Maia
Currently, few treatments are available for craving in general, and none of them have received approval for cannabis craving. The objective of this review is to evaluate existing studies analysing treatments for cannabis craving and explore novel treatment possibilities for these patients. The study followed PRISMA guidelines and conducted an extensive database search. Inclusion criteria included human randomised controlled trials examining drug effects on craving symptoms. Exclusion criteria involved studies unrelated to craving, non-pharmacological treatments, duplicates, and non-English/Spanish/Portuguese articles. Our included 22 studies that investigated a wide range of compounds used for cravings related to other drugs, as well as interventions based on healthcare professionals' empirical knowledge. The current pharmacological treatments largely involve off-label drug use and the utilisation of cannabinoid-based medications, such as combinations of THC and lofexidine, oxytocin, progesterone, and N-acetylcysteine. These emerging treatments show promise and have the potential to revolutionise current clinical practices, but further investigation is needed to establish their efficacy. In this context, it is essential to consider non-pharmacological interventions, such as psychotherapy and behavioural treatments. These approaches play a crucial role in complementing pharmacological interventions and addressing the complex nature of the disorder.